A Phase 2 interventional study of IMVT-1402 in Graves' Disease, sponsored by Immunovant Sciences GmbH. Enrolling by invitation at 131 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Immunovant Sciences GmbH · Phase 2, Interventional, and Treatment
This is a long-term extension study that will rollover participants completing feeder studies IMVT-1402-2502 (NCT06727604) or IMVT-1402-2503 (NCT07018323) to evaluate the efficacy and safety of IMVT-1402 in adult participants with GD. Eligible participants will be assigned to 1 of 3 study groups (Groups A, B and C) based on their GD status at the completion of their respective feeder study.
162 studies on the registry are indexed under Graves Disease; 53 are open to participants now.
This study's planned enrollment of 372 is above the median of 60 across 104 interventional studies indexed under Graves Disease.
Browse Graves Disease studies →Immunovant Sciences GmbH is the lead sponsor of 19 studies on the registry; 5 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 5 (45%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: IMVT-1402
Dose 1 for up to 52 weeks
Percentage of Group A Participants who remain euthyroid, Off ATD, and Off IMVT-1402
Time frame: At Week 52
Percentage of Group A Participants who are euthyroid and off ATD
Time frame: At Week 26
Percentage of Group A Participants who are euthyroid and off ATD
Time frame: Up to Week 52
Percentage of Group A Participants who are euthyroid, off ATD, and off IMVT-1402
Time frame: Up to Week 52
Time to earliest date of euthyroidism, off ATD, and off IMVT-1402 to the earliest date of confirmed relapse in Group A Participants
Time frame: Up to Week 52
Percentage of Group B Participants who remain euthyroid, off ATD, and off IMVT-1402
Time frame: Up to Week 52
Percentage of Group B Participants who remain euthyroid, off ATD, and off IMVT-1402
Time frame: At Week 52
Time from Week 0 to the earliest date of confirmed relapse in Group B Participants
Time frame: Up to Week 52
Percentage of Group C Participants who remain euthyroid, off ATD, and off IMVT-1402
Time frame: Up to Week 52
Percentage of Group C Participants who remain euthyroid, off ATD, and off IMVT-1402
Time frame: At Week 52
Time From Week 0 to the earliest date of confirmed relapse in Group C Participants
Time frame: Up to Week 52
Percentage of Group A Participants who are euthyroid, off ATD, and seronegative for TRAb
Time frame: At Week 26
Percentage of Group A Participants who are euthyroid, off ATD, and seronegative for TRAb
Time frame: Up to Week 52
Showing the first 100 of 131 sites across 11 countries. Choose a country and city above to see the rest.
Plan to share: No
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Imeroprubart
Immunovant Sciences GmbH